Novartis to acquire neuroscience firm Cadent Therapeutics for up to $770m
Dec 17, 2020 - Marketline Newswire
Mergers and Acquisitions
Novartis has entered into a definitive agreement to acquire all of the outstanding capital stock of US-based neuroscience company Cadent Therapeutics for a total potential consideration of up to $770m.
Under the deal, Cadent will receive an upfront payment of $210m and is eligible for milestone payments of up to $560m. With this acquisition, Novartis will gain complete rights to Cadent's neuroscience portfolio, including its NMDAr programme, which features two clinical programmes - CAD-930...
Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.
Are you ready to take your business development to the next level with RelSci Professional?
Nurture your network with daily alerts that notify you when your relationships make news
Map your relationships to any target or prospect to identify a warm introduction
Access unlimited deep dossiers on over 8 million decision makers
Best of all, you can try out all these powerful business development tools absolutely free for 30 days!
Check out News Home to stay on top of the people and organizations you care most about.
